Goldenwell Biotech, Inc. (OTC: GWLL)

Goldenwell Biotech, Inc. operates in the biotechnology industry, focusing on the development and production of polypeptide-based health products. The company specializes in creating bioactive peptides derived from various animal tissues, which are designed to support human health and wellness. Goldenwell Biotech's products are formulated to be easily absorbed by the human body, offering potential benefits such as improved cardiovascular health, enhanced collagen production, and support for joint health.

The company generates revenue through the sale of its proprietary health products, which include polypeptide freeze-dried powders and solid tablet products. Goldenwell Biotech's primary products are Ji Mai, Double Proline AG, Cartilage Peptide, Se Plus, Sugar Master, and DNA Repair. These products cater to a broad customer base seeking health supplements and wellness solutions. The company's products are designed to be used by individuals looking to improve their overall health, particularly those interested in cardiovascular support, collagen enhancement, joint health, and general wellness.

• Polypeptide Freeze-dried Powder Segment: This segment includes products like Ji Mai, Double Proline AG, and Cartilage Peptide. Ji Mai is a bovine cardiac vascular active peptide aimed at supporting cardiovascular health. Double Proline AG, also known as 3D Active Collagen Peptide, is designed to promote collagen production and skin health. Cartilage Peptide, or Type II collagen peptide, targets joint health and support. These products are marketed to health-conscious consumers looking for bioactive peptides to enhance their well-being.

• Solid Tablets Products Segment: This segment features products such as Se Plus and Sugar Master. Se Plus utilizes the stabilizing properties of amino acids and antioxidants, targeting middle-aged and elderly individuals, as well as those exposed to pollution or selenium deficiency. Sugar Master is formulated to maximize the harvest of bio-actives from plant matter, aiming to support overall health and wellness. This segment caters to consumers seeking convenient, solid-form health supplements.

Goldenwell Biotech, Inc. positions itself within the competitive biotechnology and health supplement industry by leveraging exclusive license agreements for its technology and packaging designs. The company has entered into agreements with Australian Trefoil Health Technologies Pty Ltd and Ji Lin JZY Biotech Inc., which provide it with access to proprietary technologies for its products. These agreements cover territories worldwide, except China, and expire in 2025 and 2035, respectively. The company's competitive advantages include its focus on bioactive peptides, low-temperature extraction techniques, and the use of high-quality raw materials. However, specific key competitors are not mentioned in the filing.

The general customer base for Goldenwell Biotech, Inc. includes health-conscious individuals seeking bioactive peptide supplements to support various aspects of their well-being. The company's products are designed to appeal to a broad range of consumers, from those looking to improve cardiovascular health to individuals interested in enhancing collagen production and joint support. The target audience also includes middle-aged and elderly individuals, as well as those exposed to pollution or selenium deficiency. While specific customer names are not provided, the company's products are positioned to attract a diverse group of health-conscious consumers.